LOGIN  |  REGISTER
Chimerix

LifeMD to Participate in Upcoming Investor Conferences and Panel Discussions

November 10, 2023 | Last Trade: US$14.05 0.25 -1.75

NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that management will be participating in two upcoming investor conferences and a panel discussion.

  • Cantor Fitzgerald GLP-1 Panel: Payor vs. Provider Perspective, November 13, 2023. Justin Schreiber, Chief Executive Officer of LifeMD, will participate in a panel discussion with Andrew Baskin, M.D., Independent Consultant and formerly the Vice President, National Medical Director at Aetna, Inc. regarding their perspectives on GLP-1s.
  • BTIG Digital Health Forum, November 21, 2023. Mr. Schreiber will participate in a panel discussion titled “Using the Platform Approach” at 12:00 p.m. Eastern time and will be available for one-on-one virtual meetings.
  • Sidoti’s Small-Cap Virtual Conference, December 6-7, 2023. Management will be presenting a corporate overview and will be hosting one-on-one meetings with investors. To register for the conference, visit www.sidoti.com/events. Registration is free and investors are not required to be a Sidoti client.

About LifeMD, Inc.
LifeMD is a leading provider of virtual primary care. LifeMD offers telemedicine, laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s health, women’s health, allergy & asthma, and dermatology. Leveraging a vertically-integrated, proprietary digital care platform, a 50-state affiliated medical group, and a US-based patient care center, LifeMD is elevating healthcare by increasing access to top-notch and affordable care. For more information, please visit LifeMD.com.

Company Contact
LifeMD, Inc.
Marc Benathen, CFO
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact
This email address is being protected from spambots. You need JavaScript enabled to view it.


C4 Therapeutics

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page